Recent News

• 06.10.2025 - Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
• 05.29.2025 - Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
• 05.23.2025 - Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
• 05.22.2025 - Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
• 05.22.2025 - Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

Recent Filings

• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 8-K Current report
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.23.2025 - 8-K Current report